U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07146191) titled 'RE104 Radiolabeled Mass Balance (hAME) Study' on Aug. 13.
Brief Summary: The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers . This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hours after SC dosing of [14C]-RE104.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Participant Study
Intervention:
DRUG: 2-[14C]-RE104 for Injection
Single, subcutaneous dose of 2-[14C]-RE104 for Injection
Recruitment Status: NOT_Y...